Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BRD2 Double Nickase Plasmid (h): sc-402584-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BRD2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- BRD2 Double Nickase Plasmid (h) and BRD2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting BRD2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BRD2 Antibody (G-4): sc-393720
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BRD2 Double Nickase Plasmid (h) | sc-402584-NIC | 20 µg | $410.00 | |||
BRD2 Double Nickase Plasmid (h2) | sc-402584-NIC-2 | 20 µg | $410.00 |
BRD2 (bromodomain containing 2) is a member of the BET family of epigenetic reader proteins that binds acetylated lysine residues on histone tails via tandem bromodomains to regulate transcriptional programs. Through interactions with chromatin and transcriptional complexes, BRD2 contributes to RNA polymerase II–dependent gene expression, cell-cycle progression, and stimulus-responsive signaling, including inflammatory and stress-associated pathways. BRD2-dependent chromatin occupancy influences enhancer and promoter activity, linking histone acetylation states to coordinated control of proliferation and differentiation. Dysregulated BET signaling, including altered BRD2 activity, has been associated with oncogenic transcriptional networks and immune-mediated disease biology in experimental systems.
BRD2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the BRD2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within BRD2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt BRD2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of BRD2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.